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Abstract
Next-generation sequencing (NGS) techniques allow high-throughput detection
of a vast amount of variations in a cost-efficient manner. However, there still are
inconsistencies and debates about how to process and analyse this ‘big data’. To
accurately extract clinically relevant information from genomics data, choosing
appropriate tools, knowing how to best utilize them and interpreting the results
correctly is crucial. This chapter reviews state-of-the-art bioinformatics approaches
in clinically relevant genomic variant detection. Best practices of reads-to-variant
discovery workflows for germline and somatic short genomic variants are presented
along with the most commonly utilized tools for each step. Additionally, methods
for detecting structural variations are overviewed. Finally, approaches and current
guidelines for clinical interpretation of genomic variants are discussed. As empha-
sized in this chapter, data processing and variant discovery steps are relatively well-
understood. The differences in prioritization algorithms on the other hand can be
perplexing, thus creating a bottleneck during interpretation. This review aims to
shed light on the pros and cons of these differences to help experts give more
informed decisions.
Keywords: genomics, NGS, variant discovery
1. Introduction
Whole genome sequencing (WGS) and whole exome sequencing are next-
generation sequencing (NGS) technologies that determine the full and protein-
coding genomic sequence of an organism, respectively. Deep sequencing of
genomes improves understanding of clinical interpretation of genomic variations.
Analyzing NGS data with the aim of understanding the impact and the importance
of genomic variations in health and disease conditions is crucial for carrying the
personalized medicine applications one step further.
One of the main obstacles for reaching the full potential of WES/WGS in
personalized medicine is bioinformatics analysis, which mostly requires strong
computational power. Analysis of WES/WGS data with publicly or commercially
available algorithms and tools require a proper computational infrastructure in
addition to an at least basic understanding of NGS technologies. Second, almost all
publicly available algorithms and tools focus on a single aspect of the entire process
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and do not provide a workflow that can aid the researcher from start to finish.
Lastly, there are no gold standards for translating WES/WGS into clinical knowl-
edge, since different diseases need different strategies for the basic analysis to
obtain the genomic variants as well as further analyses, including disease-specific
interpretation and prioritization of the variants.
A comprehensive workflow that can be applied for WES/WGS data analysis is
composed of the following steps:
a. Quality control
• Evaluation of the quality of FASTQ data
• Trimming of the low-quality reads and removal of adaptors (if necessary)
b.Sequence alignment
c. Post-alignment processing
• Marking PCR duplicates
• Base quality score recalibration (BQSR)
d.Variant discovery
e. Downstream analyses
• Filtration of genomic variations
Figure 1.
An example single-sample variant discovery workflow. Each step is labelled in the black rectangles. The most
widely used tools for each operation are also presented.
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• Annotation via a variant annotation tool
• Interpretation/prioritization of genomic variations
An example reads-to-variants workflow is visualized in Figure 1, highlighting
the input and output, a brief description, and the tools that can be utilized in each
step. While we present the most widely used tools, we would like to emphasize that
there are a great variety of tools/algorithms that can be utilized for each process.
Through the rest of this chapter, we give a brief outline of the purpose of each
step and try to provide a basic understanding of a state-of-the-art workflow for the
detection and interpretation of genomic variations. While there are countless
experimental designs, including WES/WGS and targeted (gene panel) sequencing,
the workflow presented here is applicable for all designs, occasionally requiring
slight modifications. We particularly focus on the detection and interpretation of
germline short variants, namely, single nucleotide variations (SNVs) and germline
short insertion or deletion events (indels). However, outlines of analyses for
somatic variants and for structural variations (SVs) are also presented. Finally,
current approaches and tools for clinical interpretation of genomic variations are
discussed.
2. Detection of genomic variations
Detection of genomic variations beginning from raw read data is a multistep task
that can be executed using numerous tools and resources. The workflow outlined in
the introduction section is laid out in detail in this section, including the best
practice recommendations and common pitfalls.
2.1 Acquisition of raw read data: the FASTQ file format
The raw data from a sequencing machine are most widely provided as FASTQ
files, which include sequence information, similar to FASTA files, but additionally
contain further information, including sequence quality information.
A FASTQ file consists of blocks, corresponding to reads, and each block consists
of four elements in four lines (Figure 2).
The first line contains a sequence identifier and includes an optional description
of sequencing information (such as machine ID, lane, tile, etc.). The raw sequence
letters are presented in line 2. The third line begins with a “+” sign and optionally
contains the same sequence identifier. The last line encodes the quality score for the
sequence in line 2 in the form of ASCII characters. While specific scoring measures
might differ among platforms, Phred Score (Qphred = -10log10P, where P being the
probability of misreading any given base) is the most widely used.
2.2 Quality control
In general, the raw sequence data acquired from a sequencing provider is not
immediately ready to be used for variant discovery. The first and most important
Figure 2.
Example FASTQ file format.
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step of the WES/WGS analysis workflow following data acquisition is the quality
control (QC) step. QC is the process of improving raw data by removing any
identifiable errors from it. By performing QC at the beginning of the analysis,
chances encountering any contamination, bias, error, and missing data are
minimized.
The QC process is a cyclical process, in which (i) the quality is evaluated, (ii) QC
is stopped if the quality is adequate, and (iii) a data altering step (e.g., trimming of
low-quality reads, removal of adapters, etc.) is performed, and then the QC is
repeated beginning from step (i).
The most commonly used tool for evaluating and visualizing the quality of
FASTQ data is FastQC (Babraham Bioinformatics, n.d.), which provides compre-
hensive information about data quality, including but not limited to per base
sequence quality scores, GC content information, sequence duplication levels, and
overrepresented sequences (Figure 3). Alternatives to FastQC include, but are not
limited to, fastqp, NGS QC Toolkit, PRINSEQ, and QC-Chain.
Below, QC approaches for the most commonly encountered data quality issues
are discussed: adapter contamination and low-quality measurements toward the 50
and 30 ends of reads.
Adapters are ligated to the 50 and 30 ends of each single DNA molecule during
sequencing. These adapter sequences hold barcoding sequences, forward/reverse
primers, and the binding sequences to immobilize the fragments to the flow cell and
allow bridge amplification. Since the adapter sequences are synthetic and are not
seen in any genomic sequence, adapter contamination often leads to NGS alignment
errors and an increased number of unaligned reads. Hence, any adapter sequences
need to be removed before mapping. In addition to adapter removal, trimming can
be performed to discard any low-quality reads, which generally occur at the 50 and
30 ends.
There is an abundance of tools for QC, namely, Trimmomatic [1], CutAdapt [2],
AlienTrimmer [3], Skewer [4], BBDuk [5], Fastx Toolkit [6], and Trim Galore [7].
Figure 3.
An example FastQC result.
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In addition to these stand-alone tools, R packages for QC, such as PIQA and
ShortRead, are also available.
While QC is the most important step of NGS analysis, one must keep in mind
that once basic corrections (such as the ones described above) are made, no amount
of further QC can produce a radically better outcome. QC cannot simply turn bad
data into good data. Moreover, it is also important to remember that because QC
may also introduce error that can affect the analysis, it is vital never to perform
error correction on data that does not need it.
2.3 Sequence alignment
In order to find the exact locations of reads, each must be aligned to a reference
genome. Efficiency and accuracy are crucial in this step because large quantities of
reads could take days to align and a low-accuracy alignment would cause inade-
quate analyses. For humans, the most current and widely used reference sequences
are GRCh37 (hg19) and GRCh38 (hg38). Similar to any bioinformatics problem,
there are a great number of tools for alignment of sequences to the reference
genome, to name a few, BWA [8], Bowtie2 [9], novoalign [10], and mummer [11].
After aligning, a Sequence Alignment Map (SAM) file is produced. This file
contains the reads aligned to the reference. The binary version of a SAM file is
termed a Binary Alignment Map (BAM) file, and BAM files are utilized for random-
access purposes. The SAM/BAM file consists of a header and an alignment section.
The header section contains contigs of aligned reference sequence, read groups
(carrying platform, library, and sample information), and (optionally) data
processing tools applied to the reads. The alignment section includes information on
the alignments of reads.
2.4 Post-alignment processing
One of the key steps in any reads-to-variants workflow is post-alignment data
processing to produce analysis-ready BAM files. This step includes data clean-up
operations to correct for technical biases: marking duplicates and recalibration of
base quality scores.
During the preparation of samples for sequencing, PCR duplicates arise at the
step of PCR amplification of fragments. Since they share the same sequence and the
same alignment position, they can lead to problems in variant detection. For exam-
ple, during SNV calling, false-positive variants may arise as some alleles may be
overrepresented due to amplification biases. To overcome this issue, PCR duplicates
are marked with a certain tag using an algorithm (MarkDuplicates) available in the
tool Picard [12]. Marking duplicates constitutes a major bottleneck since it involves
making a large number of comparisons between all the read pairs. Thus, the major-
ity of the effort in optimizing the runtime of reads-to-variants workflows is focused
on this step.
As aforementioned, NGS platforms provide information on the quality of each
base that they measure in the Phred Score format. The relationship of a Phred Score
with accuracy is straightforward: a Phred Score of 10 represents 90% accuracy, 20
equals 99%, 30 equals 99.9%, and so on. The raw scores produced by the sequencing
machine are prone to technical errors, leading to over- or underestimated base
quality scores. Base quality score recalibration (BQSR) is a machine learning
approach that models these errors empirically and readjusts the base quality scores
accordingly. Through this recalibration, more accurate and reliable base quality
scores are achieved, which in turn improves the reliability of the downstream steps
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in further analyses. The most widely used tool for BQSR is provided by the Genome
Analysis Toolkit (GATK) [13].
After these post-alignment data processing operations, an analysis-ready BAM
file is obtained.
2.5 Short variant discovery
In this section, approaches for the discovery of germline SNV and indels are
discussed. In the following sections, approaches for the discovery of somatic short
variants and of structural variations are outlined.
Following data processing steps, the reads are ready for downstream analyses,
and the following step is most frequently variant calling. Variant calling is the
process of identifying differences between the sequencing reads, resulting from
NGS experiments and a reference genome. Countless variant callers have been and
are being developed for accomplishing this challenging task as alignment and
sequencing artifacts complicate the process of variant calling. For recent studies
comparing different variant callers, see [14–16]. Methods for detecting short vari-
ants can be broadly categorized into “probabilistic methods” and “heuristic-based
algorithms.” In probabilistic methods, the distribution of the observed data is
modeled, and then Bayesian statistics is utilized to calculate genotype probabilities.
In contrast, in heuristic-based algorithms, variant calls are made based on a number
of heuristic factors, such as read quality cutoffs, minimum allele counts, and bounds
on read depth. Whereas heuristic-based algorithms are not as widely used, they can
be robust to outlying data that violate the assumptions of probabilistic models.
The most widely used state-of-the-art variant callers include, but are not limited
to, GATK-HaplotypeCaller [13], SOAPsnp [17], SAMTools [18], bcftools [18],
Strelka [19], FreeBayes [20], Platypus [21], and DeepVariant [22]. We would like to
emphasize that for WES/WGS, a combination of different variant callers outper-
forms any single method [23].
2.6 Filtration of variants
Following the variant calling step, raw SNV and indels in the Variant Call
Format (VCF) are obtained. These should then be filtered either through applying
hard filters to the data or through a more complex approach such as GATK’s Variant
Quality Score Recalibration (VQSR).
Hard filtering is applied by filtering via thresholds for metrics such as
QualByDepth, FisherStrand, RMSMappingQuality, MappingQualityRankSumTest,
ReadPosRankSumTest, and StrandOddsRatio.
VQSR, on the other hand, relies on machine learning to identify annotation
profiles of variants that are likely to be real. It requires a large training dataset
(minimum 30WES data, at least one WGS data if possible) and well-curated sets of
known variants. The aim is to assign a well-calibrated probability to each variant
call to create accurate variant quality scores that are then used for filtering.
The accuracy of variant calling is also affected by coverage. Coverage can be
broadly defined as the number of unique reads that include a given nucleotide.
Coverage is affected by the accuracy of alignment algorithms and by the
“mappability” of reads. Coverage can be utilized for both the filtration of variants
and for a general evaluation of the sequencing experiment. Tools for assessing
coverage information include GATK [13], BEDTools [24], Sambamba [25], and
RefCov [26].
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For validation of variants and for detecting sequencing artifacts, Integrative
Genomics Viewer (IGV) [27] can be used to visualize the processed reads. In
addition to this in silico evaluation, Sanger sequencing can be performed.
2.7 Variant annotation
Variant annotation is yet another critical step in the WES/WGS analysis
workflow. The aim of all functional annotation tools is to annotate information of
the variant effects/consequences, including but not limited to (i) listing which gene
(s)/transcript(s) are affected, (ii) determination of the consequence on protein
sequence, (iii) correlation of the variant with known genomic annotations (e.g.,
coding sequence, intronic sequence, noncoding RNA, regulatory regions, etc.), and
(iv) matching known variants found in variant databases (e.g., dbSNP [28], 1000
Genomes Project [29], ExAc [30], gnomAD [31], COSMIC [32], ClinVar [33], etc.).
The consequence of each variant is expressed through Sequence Ontology (SO)
terms. The severity and impact of these consequences are often indicated using
qualifiers (e.g., low, moderate, high).
Many annotation tools utilize the predictions of SNV/indel deleteriousness pre-
diction methods, to name a few, SIFT [34], PolyPhen-2 [35], LRT [36],
MutationTaster [37], MutationAssessor [38], FATHMM [39], GERP++ [40], PhyloP
[41], SiPhy [42], PANTHER-PSEP [43], CONDEL [44], CADD [45], CHASM [46],
CanDrA [47], and VEST [48].
Annotation can have a strong influence on the ultimate conclusions during
interpretation of genomic variations as incomplete or incorrect annotation
information will result in the researcher/clinician to overlook potentially relevant
findings.
Once the analysis-ready VCF is produced, the genomic variants can then be
annotated using a variety of tools and a variety of transcript sets. Both the choice of
annotation software and transcript set (e.g., RefSeq transcript set [49], Ensembl
transcript set [50]) have been shown to be important for variant annotation [51].
The most widely used functional annotation tools include but are not limited to
AnnoVar [52], SnpEff [53], Variant Effect Predictor (VEP) [54], GEMINI [55],
VarAFT [56], VAAST [57], TransVar [58], MAGI [59], SNPnexus [60], and
VarMatch [61]. Below some of the popular tools are briefly described:
AnnoVar: AnnoVar is one of the most popular tools for annotation of SNV and
indels. AnnoVar takes a simple text-based format that includes chr, start, end, ref,
alt, and optional field(s) as an input. To use AnnoVar, one must convert VCF file
format to the AnnoVar input file format. The tool returns a single annotation for
each variant. If there exists more than one transcript for a specific variant resulting
in different consequences, AnnoVar chooses the transcript according to the gene
definition set by the user.
SnpEff: SnpEff is an open-source tool that annotates variants and predicts their
effects on genes by using an interval forest approach. SnpEff annotates variants
based on their genomic locations such as intronic, untranslated region, upstream,
downstream, splice site, or intergenic regions and predicts coding effects. snpEff
also generates extensive report files and is easily customizable.
VEP:VEP is an open-source, free-to-use toolset for the analysis, annotation, and
prioritization of genomic variants in coding and noncoding regions. VEP is one of
the few annotation tools that annotates variants in regulatory regions.
GEnome MINIng (GEMINI): GEMINI is a flexible software package for
exploring all forms of human genetic variations. Different from most other annota-
tion tools, GEMINI integrates genetic variation with a set of genome annotations.
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While the abovementioned are all variant annotation tools, it might be wise to put
GEMINI in a different category as it has other built-in tools to make further analysis
of the variants easier.
2.8 Somatic genomic variations
The workflow for identifying somatic short variants (somatic SNV/indels) is
nearly identical to the germline short variant discovery workflow (Figure 4).
However, several differences exist. Firstly, for the discovery of somatic genomic
variations, sequencing both tumor tissue and a matched normal sample (blood,
adjacent normal tissue, etc.) is mostly (but not necessarily) preferred. The QC,
alignment, and post-alignment data processing steps are identical and are
performed for both the tumor and normal data, separately. The main difference is
the variant calling step, where both the tumor and normal processed read data are
utilized to identify somatic SNV/indels, i.e., short variants that are present in the
tumor but not in the normal. Some tools (such as GATK-MuTect2) can utilize
additional information from a panel of normals, a collection of normal samples
(typically larger than 40) that are believed to have no somatic variants, processed in
the same manner at each step and the purpose of which is to capture recurrent
technical artifacts.
Several tools exist for tumor-normal somatic variant calling, to name a few,
GATK - MuTect2 [13], VarScan2 [62], Strelka [19], SomaticSniper [63], SAMtools
[18], SomaticSeq [64], FreeBayes [65], CaVEMan [66], and FaSD-somatic [67]. For
further information on somatic variant calling, we encourage the reader to refer to a
recent and comprehensive review on somatic variant calling algorithms [16].
Filtration of the raw SNV and indels also differs for the somatic workflow.
Several different approaches exist for the filtration of raw somatic variants. Most
Figure 4.
An example somatic variant discovery workflow. Each step is labelled in the black rectangles. Most widely used
tools for each operation are also presented. As can be seen in the diagram, the processing steps until the variant
calling step are performed for both the normal and tumor data, separately.
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frequently, tumor-specific metrics including the estimation of tumor heterogeneity
and cross-sample contamination are used in addition to the aforementioned metrics
for detection of sequencing/alignment artifacts.
While all the annotation tools, presented in the “variant annotation” section, can
be used to annotate somatic variants, a number of tools that provide cancer-specific
annotation in addition to general annotation are available. Two popular examples
are Oncotator [68] and CRAVAT [69]. Oncotator, a widely used cancer-specific
annotation tool, is often preferred for the annotation of somatic short variants.
Oncotator provides variant- and gene-centric information relevant to cancer
researchers, utilizing resources including but not limited to the Catalogue of
Somatic Mutations in Cancer (COSMIC) [70], the Cancer Gene Census [71], Cancer
Cell Line Encyclopedia [72], The Cancer Genome Atlas (TCGA), and Familial
Cancer Database [73].
2.9 Structural variations
So far, we focused only on the discovery of small-scale genomic variations
(SNVs and indels). There also exist large-scale (1 kb and larger) genomic variations,
which either be copy number variations (CNV) or chromosomal rearrangement
events (including translocations, inversions, and duplications).
2.9.1 Copy number variations
CNV is a frequent form of critical genetic variation that results in an abnormal
number of copies of large genomic regions (either gain or loss events). CNV is
clinically relevant, as they may play vital roles in disease processes, especially
during oncogenesis. It is possible to detect CNVs using WES/WGS data. Several
different approaches exist for this purpose [74]:
i. Paired-end mapping strategy detects CNVs through discordantly mapped
reads. Tools utilizing this approach include BreakDancer, PEMer,
VariationHunter, commonLAW, GASV, and Spanner.
ii. Split read-based methods use the incompletely mapped read from each read
pair to identify small CNVs. Split read-based tools include AGE, Pindel,
SLOPE, and SRiC.
iii.Read depth-based approach detects CNV by counting the number of reads
mapped to each genomic region. Tools using this approach include GATK,
SegSeq, CNV-seq, RDXplorer, BIC-seq, CNAseq, cn.MOPS, jointSLM,
ReadDepth, rSW-seq, CNVnator, CNVnorm, CMDS, mrCaNaVar, CNVeM,
and cnvHMM.
iv.Assembly-based approach detects CNVs by mapping contigs to the reference
genome. Tools using this approach include Magnolya, Cortex assembler, and
TIGRA-SV.
v.Combinatorial approach combines read depth and paired-end mapping
information to detect CNVs. Tools using this approach include NovelSeq,
HYDRA, CNVer, GASVPro, Genome STRiP, SVDetect, inGAP-sv, and SVseq.
In addition to the noise and artifacts caused by WES/WGS, tumor complexity
(the strongest factor being tumor heterogeneity) makes the detection of somatic
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CNVs more challenging. To overcome this challenge, numerous tools have been
developed. Widely used tools for detecting specifically somatic CNVs include
ADTEx [75], CONTRA [76], cn.MOPS [77], ExomeCNV [78], VarScan2 [62],
SynthEx [79], Control-FREEC [80], GATK [13], and CloneCNA [81].
2.9.2 Chromosomal rearrangements
Chromosomal rearrangements are variations in chromosome structure whose
impact on genetic diversity and disease susceptibility has become increasingly evi-
dent [82]. Per SO, numerous types of rearrangements exist: duplication, deletion,
insertion, mobile element insertion, novel sequence insertion, tandem duplication,
inversion, intrachromosomal breakpoint, interchromosomal breakpoint, transloca-
tion, and complex SVs. Similar to CNV detection, there are multiple approaches for
rearrangement detection: read-pair, split-read, read-depth, and assembly
approaches. The underlying aims of each of these approaches are very similar to
those for CNV detection. As for CNV detection, countless tools have been devel-
oped for the detection of rearrangement variations, including but not limited to
Breakdancer [83], GRIMM [84], LUMPY [85], BreaKmer [86], BreakSeek [87],
CREST [88], DELLY [89], HYDRA [90], MultiBreak-SV [91], Pindel [92],
SoftSearch [93], SVdetect [94], and TIGRA-SV [95].
Lastly, we would like to point out that long reads (enabled by the emergence of
so-called third-generation sequencing technologies) allow for more accurate and
reliable determination of SVs with the development of novel algorithms that spe-
cifically exploits these long reads [96].
3. Clinical interpretation of genomic variations
Perhaps the most challenging process in WES/WGS analysis is the clinical inter-
pretation of genomic variations. While WES/WGS is rapidly becoming a routine
approach for the diagnosis of monogenic and complex disorders and personalized
treatment of such disorders, it is still challenging to interpret the vast amount of
genomic variation data detected through WES/WGS [97].
There exist numerous standardized widely accepted guidelines for the evalua-
tion of genomic variations obtained through NGS such as the American College of
Medical Genetics and Genomics (ACMG), the EuroGentest, and the European
Society of Human Genetics guidelines. These provide standards and guidelines for
the interpretation of genomic variations and include evidence-based recommenda-
tions on aspects including the use of literature and database and the use of in silico
predictors, criteria for variant interpretation, and reporting.
In addition to variant-dependent annotation such as allele frequency (e.g., in
1000 Genomes [29], ExAc [30], gnomAD [31]), the predicted effect on protein and
evolutionary conservation, disease-dependent inquiries such as mode of inheri-
tance, co-segregation of variant with disease within families, prior association of the
variant/gene with disease, investigation of clinical actionability, and pathway-based
analysis are required for the interpretation of genomic variants.
Databases such as ClinVar [33], HGV databases [98], OMIM [99], COSMIC
[100], and CIViC [101] are excellent resources that can aid interpretations of
clinical significance of germline and somatic variants for reported conditions. The
availability of shared genetic data in such databases makes it possible to identify
patients with similar conditions and aid the clinician to make a conclusive diagnosis.
While one may perform interpretation of genomic variations completely manu-
ally after annotation and filtering of variants, there are several tools to aid in
10
Bioinformatics Tools for Detection and Clinical Interpretation of Genomic Variations
interpretation and prioritization of these variants, including Ingenuity Variant Anal-
ysis [102], BaseSpace Variant Interpreter [103], VariantStudio [104], KGGSeq [105],
PhenoTips [106], VarElect [107], PhenoVar [108], InterVar [109], VarSifter [110],
eXtasy [111], VAAST [57], and Exomiser [112]. For personalized oncology purposes,
numerous cancer-specific tools exist, specifically developed to determine driver
genes/mutations as well as to aid in interpretation of somatic variants. Some of the
most widely used somatic interpretation tools are PHIAL, PCGR, and HitWalker2.
Pathway analysis is another powerful component that can enhance the interpre-
tation of genomic variations. Pathway analysis can be broadly defined as a group of
methods incorporating biological information from public databases to simplify
analysis by grouping long lists of genes into smaller sets of related genes (for a
comprehensive review on pathway analysis, see [113]). Pathway analysis improves
the detection of causal variants by incorporating biologic insight. The clinician can
gain a better understanding of the functions of rare genetic variants of unknown
clinical significance in the context of biological pathways. While the gene carrying
the variant may not be related to the phenotype, its associated genes in the pathway
might be causally related to the phenotype at hand. Moreover, through pathway
analysis, the role of multiple variants and their interaction on disease formation can
be discovered.
Countless tools for pathway analysis exist. Some of the widely used pathway
analysis tools are GSEA [114], DAVID [115], IPA [116], SPIA [117], pathfindR
[118], enrichr [119], reactomePA [120], MetaCore [121], and PathVisio [122].
Additionally, many different pathway resources exist, the most popular of which
are Kyoto Encyclopedia of Genes and Genomes [123], Reactome [124],
WikiPathways [125], MSigDb [126], STRINGDB [127], Pathway Commons [128],
Ingenuity Knowledge Base [129], and Pathway Studio [130].
In silico interpretation often fails to provide conclusive evidence for pathoge-
nicity of genomic variations [131]. Furthermore, these in silico interpretations are
mostly only well-supported predictions (this is especially true for VUS). It is there-
fore vital to perform functional validation to understand the functional conse-
quences of genetic variants, provide a conclusive diagnosis, and inform the patient
on the disease course. Functional validation can be performed using different model
systems (e.g., patient cells, model cell lines, model organisms, induced pluripotent
stem cells) and performing the suitable type of assay (e.g., genetic rescue,
overexpression, biomarker analysis).
4. Conclusion
The advancements in NGS, the increasing availability and applicability of WES/
WGS analysis due to decrease in cost, and the development of countless bioinfor-
matics methods and resources enabled the usage of WES/WGS to detect, interpret,
and validate genomic variations in the clinical setting.
As we attempted to describe in this chapter, WES/WGS analysis is challenging,
and there are a great number of tools for each step of variation discovery. There-
fore, one must carefully evaluate the advantages and disadvantages and suitability
of different tools (depending on the specific application) before adapting the “opti-
mal” one into the variation discovery workflow. An optimal and coordinated com-
bination of tools is required to identify the different types of genomic variants,
described here. On the one hand, an efficient analysis strategy needs to adopt one or
more methods for the detection of each type of variant and, on the other hand,
needs to integrate results for the different types of variants into a single compre-
hensive solution.
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We attempted to describe the best practices for variant discovery, outlining the
fundamental aspects. We hope to have provided a basic understanding of WES/
WGS analysis as we believe awareness of the steps involved as well as the challenges
involved at each step is important to understand how each piece may affect the
downstream steps (and eventually affect interpretation). As emphasized through-
out the chapter, substantial (or even minor) changes at any step can fundamentally
alter the outcomes in the later stages.
While there is no definite gold standard for the interpretation of genomic vari-
ations, we attempted to briefly describe the currently available and widely used
guidelines, tools, and resources for clinical evaluation of genomic variations.
In the following years, with the advancements in bioinformatics, increasing
cooperation between the clinician and bioinformatician and large-scale efforts
(such as IRDiRC [132], TCGA [133], and ICGC [134]), we expect that a greater
focus will be on developing novel tools for clinical interpretation of genomic varia-
tions. Cooperation between multiple disciplines is vital to improve the existing
approaches as well as to develop novel approaches and resources.
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